Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis
复制标题
系统性硬化症相关进行性间质性肺病患者接受吡非尼酮治疗后肺功能得到改善
作者：
Z. Udwadia;J. Mullerpattan;C. Balakrishnan;L. Richeldi
吡非尼酮是一种抗纤维化药物，已被批准用于治疗特发性肺纤维化（IPF）患者。然而，其在由其他原因如系统性硬化症（SSc）引起的间质性肺病（ILD）中的作用尚不清楚。我们报告了1例SSc相关ILD患者，吡非尼酮治疗后肺功能出现主观和客观改善。
Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associated ILD who showed a subjective as well as objective improvement in lung function with pirfenidone.